Linked Life Data

21648207

Source:http://linkedlifedata.com/resource/pubmed/id/21648207

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
115
pubmed:dateCreated
2011-6-8
pubmed:abstractText
When severe asthma persists despite high-dose inhaled corticosteroid therapy, it is better to switch to oral corticosteroid therapy than to add another asthma drug. In 2007, we concluded that omalizumab had a negative risk-benefit balance in this setting. In mid-2010, we found no new data on the efficacy of omalizumab. At best, omalizumab prevents 1 emergency room visit approximately every 2.5 years. Post-marketing follow-up data confirm the infectious adverse effects and hypersensitivity reactions associated with omalizumab, and show that anaphylactic reactions can occur several days after an injection. A possible increase in the risk of cancer has not yet been ruled out. New adverse effects associated with omalizumab have emerged, including serious cardiac effects and severe thrombocytopenia. In practice, despite longer followup, the efficacy of omalizumab remains uncertain, while new, sometimes serious adverse effects have emerged. It is better to adjust standard treatments to the individual's situation than to risk using omalizumab.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
T
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1167-7422
pubmed:issnType
Print
pubmed:volume
20
pubmed:owner
NLM
pubmed:pagination
90-2
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Omalizumab: a second look in severe persistent asthma: new adverse effects.
pubmed:publicationType
Journal Article